{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:59:56Z","timestamp":1785405596991,"version":"3.56.0"},"reference-count":52,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003975","name":"Israel Cancer Association","doi-asserted-by":"publisher","award":["20160109"],"award-info":[{"award-number":["20160109"]}],"id":[{"id":"10.13039\/501100003975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["Merck Sharp & Dohme LLC"],"award-info":[{"award-number":["Merck Sharp & Dohme LLC"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["a subsidiary of Merck & Co."],"award-info":[{"award-number":["a subsidiary of Merck & Co."]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["Inc."],"award-info":[{"award-number":["Inc."]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["Rahway"],"award-info":[{"award-number":["Rahway"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["NJ"],"award-info":[{"award-number":["NJ"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["USA"],"award-info":[{"award-number":["USA"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Pegylated liposomal doxorubicin (PLD) is a potent immunogenic cell death inducer, allowing for improved tumor-immune recognition and T-cell activation. We report a phase Ib study of combined PLD and pembrolizumab (PEM) in estrogen receptor (ER)-positive\/human epidermal growth factor receptor 2\u2013negative metastatic breast cancer (MBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Patients with MBC, who progressed on hormonal, biological, and cytotoxic chemotherapy, were eligible. Study objectives were safety, response, survival, and pharmacokinetics (PK). The study consisted of two cohorts: PLD 30 mg\/m2 once every 3 weeks and PLD 40 mg\/m2 once every 4 weeks, with PEM 200 mg once every 3 weeks in both cohorts. Responding and stable patients continued treatment until disease progression or intolerance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thirty-five patients were enrolled and received a total of 201 PLD and 257 PEM treatments. Treatment was well tolerated with no significant neutropenia, no cardiac events, and minimal hair loss. Treatment-related serious adverse events were observed in three patients. In patients receiving &amp;gt;3 cycles, cutaneous toxicity often forced treatment delays. The disease control rate was 67%, including 10 responses with median duration of 11 months. Responses of large liver metastases were observed. The median overall survival was 25 months. PLD PK was monoexponential with high peak plasma concentration, long half-life (\u223c3 days), slow clearance, and small volume of distribution in the central compartment. PEM plasma levels indicated mean half-life of \u223c11 days with high trough concentrations. Gene expression tumor profiling identified 16 genes upregulated in responders versus nonresponders, including interferon-stimulated genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The combination of PLD with PEM is well-tolerated, active, and feasible for extended treatment with durable responses. The results suggest possible contribution of PEM to the antitumor effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The combination of PLD and PEM in ER-positive MBC resulted in durable antitumor responses and median survival exceeding 2 years in a heavily pretreated patient group. These clinical observations together with the pharmacologic rationale and gene expression data have translational relevance supporting further exploration of combinations of nanomedicines with immunotherapy in this breast cancer population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0539","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:40:08Z","timestamp":1782506408000},"page":"1738-1749","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Phase Ib Study of Chemoimmunotherapy with Pegylated Liposomal Doxorubicin and Pembrolizumab in Estrogen Receptor\u2013Positive Metastatic Breast Cancer"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1332-1164","authenticated-orcid":false,"given":"Alberto A.","family":"Gabizon","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04d0szq68","id-type":"ROR","asserted-by":"publisher"}],"name":"Shaare Zedek Medical Center 1 , Hebrew University-Faculty of Medicine, Jerusalem, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9557-4634","authenticated-orcid":false,"given":"Hadar","family":"Goldvaser","sequence":"additional","affiliation":[{"name":"2Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6106-2307","authenticated-orcid":false,"given":"Adar","family":"Yaacov","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04d0szq68","id-type":"ROR","asserted-by":"publisher"}],"name":"Shaare Zedek Medical Center 1 , Hebrew University-Faculty of Medicine, Jerusalem, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9274-1866","authenticated-orcid":false,"given":"Ora S.","family":"Rosengarten","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04d0szq68","id-type":"ROR","asserted-by":"publisher"}],"name":"Shaare Zedek Medical Center 1 , Hebrew University-Faculty of Medicine, Jerusalem, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1976-8952","authenticated-orcid":false,"given":"Nathan","family":"Cherny","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04d0szq68","id-type":"ROR","asserted-by":"publisher"}],"name":"Shaare Zedek Medical Center 1 , Hebrew University-Faculty of Medicine, Jerusalem, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9574-1137","authenticated-orcid":false,"given":"Rut","family":"Isacson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04d0szq68","id-type":"ROR","asserted-by":"publisher"}],"name":"Shaare Zedek Medical Center 1 , Hebrew University-Faculty of Medicine, Jerusalem, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4381-292X","authenticated-orcid":false,"given":"Shani","family":"Breuer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04d0szq68","id-type":"ROR","asserted-by":"publisher"}],"name":"Shaare Zedek Medical Center 1 , Hebrew University-Faculty of Medicine, Jerusalem, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2347-6227","authenticated-orcid":false,"given":"Areen","family":"Abu-Remilah","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04d0szq68","id-type":"ROR","asserted-by":"publisher"}],"name":"Shaare Zedek Medical Center 1 , Hebrew University-Faculty of Medicine, Jerusalem, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3362-7064","authenticated-orcid":false,"given":"Hilary","family":"Shmeeda","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04d0szq68","id-type":"ROR","asserted-by":"publisher"}],"name":"Shaare Zedek Medical Center 1 , Hebrew University-Faculty of Medicine, Jerusalem, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0960-2601","authenticated-orcid":false,"given":"Eliahu","family":"Golomb","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04d0szq68","id-type":"ROR","asserted-by":"publisher"}],"name":"Shaare Zedek Medical Center 1 , Hebrew University-Faculty of Medicine, Jerusalem, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9268-9971","authenticated-orcid":false,"given":"Yehonatan N.","family":"Turner","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04d0szq68","id-type":"ROR","asserted-by":"publisher"}],"name":"Shaare Zedek Medical Center 1 , Hebrew University-Faculty of Medicine, Jerusalem, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3351-5719","authenticated-orcid":false,"given":"Albert","family":"Grinshpun","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04d0szq68","id-type":"ROR","asserted-by":"publisher"}],"name":"Shaare Zedek Medical Center 1 , Hebrew University-Faculty of Medicine, Jerusalem, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"2026072314412415000_bib1","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"2026072314412415000_bib2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/s0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"2026072314412415000_bib3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"2026072314412415000_bib4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/s1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026072314412415000_bib5","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"key":"2026072314412415000_bib6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"2026072314412415000_bib7","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"2026072314412415000_bib8","doi-asserted-by":"publisher","first-page":"e1008866","DOI":"10.1080\/2162402X.2015.1008866","article-title":"Trial Watch: immunogenic cell death inducers for anticancer chemotherapy","volume":"4","author":"Pol","year":"2015","journal-title":"Oncoimmunology"},{"key":"2026072314412415000_bib9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2\u2212 breast cancer: a randomized phase 3 trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat Med"},{"key":"2026072314412415000_bib10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","article-title":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial","volume":"31","author":"Loi","year":"2025","journal-title":"Nat Med"},{"key":"2026072314412415000_bib11","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/jamaoncol.2020.3524","article-title":"Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor-positive, ERBB2-negative metastatic breast cancer: a randomized clinical trial","volume":"6","author":"Tolaney","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026072314412415000_bib12","doi-asserted-by":"publisher","first-page":"e007990","DOI":"10.1136\/jitc-2023-007990","article-title":"Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial","volume":"12","author":"Andresen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026072314412415000_bib13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/bjc.2017.145","article-title":"A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)","volume":"117","author":"Weiss","year":"2017","journal-title":"Br J Cancer"},{"key":"2026072314412415000_bib14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ygyno.2020.07.028","article-title":"Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: a phase 2 clinical trial","volume":"159","author":"Lee","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2026072314412415000_bib15","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026072314412415000_bib16","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J Exp Med"},{"key":"2026072314412415000_bib17","doi-asserted-by":"publisher","first-page":"e000573","DOI":"10.1136\/bmjonc-2024-000573","article-title":"Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil\/Caelyx): an updated analysis and future perspective","volume":"4","author":"Gabizon","year":"2025","journal-title":"BMJ Oncol"},{"key":"2026072314412415000_bib18","doi-asserted-by":"publisher","first-page":"113731","DOI":"10.1016\/j.jconrel.2025.113731","article-title":"Cancer nanomedicine from a clinician-scientist perspective: lessons and prospects","volume":"382","author":"Gabizon","year":"2025","journal-title":"J Control Release"},{"key":"2026072314412415000_bib19","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1023\/a:1008365716693","article-title":"Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2","volume":"11","author":"Safra","year":"2000","journal-title":"Ann Oncol"},{"key":"2026072314412415000_bib20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"2026072314412415000_bib21","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/sj.bjc.6605961","article-title":"Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials","volume":"103","author":"Al-Batran","year":"2010","journal-title":"Br J Cancer"},{"key":"2026072314412415000_bib22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.7150\/ntno.75045","article-title":"Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model","volume":"6","author":"Islam","year":"2022","journal-title":"Nanotheranostics"},{"key":"2026072314412415000_bib23","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.neo.2015.08.004","article-title":"Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models","volume":"17","author":"Rios-Doria","year":"2015","journal-title":"Neoplasia"},{"key":"2026072314412415000_bib24","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3390\/pharmaceutics12100990","article-title":"Adjuvant antitumor immunity contributes to the overall antitumor effect of pegylated liposomal doxorubicin (Doxil\u00ae) in C26 tumor-bearing immunocompetent mice","volume":"12","author":"Takayama","year":"2020","journal-title":"Pharmaceutics"},{"key":"2026072314412415000_bib25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00280-007-0525-5","article-title":"An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin","volume":"61","author":"Gabizon","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026072314412415000_bib26","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"54","author":"Gabizon","year":"1994","journal-title":"Cancer Res"},{"issue":"6 Suppl 13","key":"2026072314412415000_bib27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/j.seminoncol.2004.08.002","article-title":"Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies","volume":"31","author":"Vail","year":"2004","journal-title":"Semin Oncol"},{"key":"2026072314412415000_bib28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2026072314412415000_bib29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0009-9236(97)90162-4","article-title":"Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi\u2019s sarcoma","volume":"61","author":"Amantea","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"2026072314412415000_bib30","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10928-017-9528-y","article-title":"Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response","volume":"44","author":"Li","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2026072314412415000_bib31","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/0008-5472.can-12-4561","article-title":"Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology","volume":"73","author":"Prabhakar","year":"2013","journal-title":"Cancer Res"},{"key":"2026072314412415000_bib32","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40487-025-00346-2","article-title":"Immunotherapy in triple-negative breast cancer","volume":"13","author":"Tiberi","year":"2025","journal-title":"Oncol Ther"},{"key":"2026072314412415000_bib33","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026072314412415000_bib34","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s40262-019-00789-7","article-title":"Immune checkpoint inhibitors in melanoma: a review of pharmacokinetics and exposure-response relationships","volume":"58","author":"Leven","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2026072314412415000_bib35","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5&lt;1037::aid-cncr13&gt;3.0.co;2-z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"key":"2026072314412415000_bib36","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.clbc.2016.06.001","article-title":"Biweekly pegylated liposomal doxorubicin (Caelyx) in heavily pretreated metastatic breast cancer: a phase 2 study","volume":"16","author":"Jehn","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"2026072314412415000_bib37","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.1200\/JCO.2004.08.157","article-title":"Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer","volume":"22","author":"Keller","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026072314412415000_bib38","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/annonc\/mdt588","article-title":"A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG","volume":"25","author":"Smorenburg","year":"2014","journal-title":"Ann Oncol"},{"key":"2026072314412415000_bib39","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"2026072314412415000_bib40","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1200\/jco.2009.26.8052","article-title":"What is the right way to administer pegylated liposomal doxorubicin in breast cancer therapy?","volume":"28","author":"Grenader","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026072314412415000_bib41","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s44222-024-00203-3","article-title":"Nanoparticle delivery to tumours: from EPR and ATR mechanisms to clinical impact","volume":"2","author":"Dasgupta","year":"2024","journal-title":"Nat Rev Bioeng"},{"key":"2026072314412415000_bib42","doi-asserted-by":"publisher","first-page":"1661872","DOI":"10.3389\/fbioe.2025.1661872","article-title":"Nanoparticle technologies for liver targeting and their applications in liver diseases","volume":"13","author":"Peng","year":"2025","journal-title":"Front Bioeng Biotechnol"},{"key":"2026072314412415000_bib43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1208\/s12248-009-9157-5","article-title":"Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease","volume":"12","author":"Tabrizi","year":"2010","journal-title":"AAPS J"},{"key":"2026072314412415000_bib44","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/imm.13114","article-title":"Cancer immune escape: MHC expression in primary tumours versus metastases","volume":"158","author":"Garrido","year":"2019","journal-title":"Immunology"},{"key":"2026072314412415000_bib45","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41416-023-02459-9","article-title":"Preoperative chemoradiotherapy induces multiple pathways related to anti-tumour immunity in rectal cancer","volume":"129","author":"Koukourakis","year":"2023","journal-title":"Br J Cancer"},{"key":"2026072314412415000_bib46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00251-008-0303-5","article-title":"Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy","volume":"60","author":"Carretero","year":"2008","journal-title":"Immunogenetics"},{"key":"2026072314412415000_bib47","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00262-008-0532-3","article-title":"Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations","volume":"57","author":"Aptsiauri","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"2026072314412415000_bib48","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat Med"},{"key":"2026072314412415000_bib49","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1158\/1078-0432.CCR-25-2570","article-title":"Pembrolizumab and paclitaxel in HR+\/HER2\u2212 breast cancer with HER2-enriched or basal-like subtypes","volume":"32","author":"Conte","year":"2026","journal-title":"Clin Cancer Res"},{"key":"2026072314412415000_bib50","doi-asserted-by":"publisher","first-page":"1522508","DOI":"10.3389\/fimmu.2024.1522508","article-title":"Radioimmunotherapy: a game-changer for advanced non-small cell lung cancer","volume":"15","author":"Xue","year":"2024","journal-title":"Front Immunol"},{"key":"2026072314412415000_bib51","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3109\/07357907.2011.605413","article-title":"New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response","volume":"29","author":"Hamilton","year":"2011","journal-title":"Cancer Invest"},{"key":"2026072314412415000_bib52","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/imm.13283","article-title":"Zoledronate promotes inflammatory cytokine expression in human CD14-positive monocytes among peripheral mononuclear cells in the presence of \u03b3\u03b4 T cells","volume":"162","author":"Takimoto","year":"2021","journal-title":"Immunology"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0539\/3809104\/crc-25-0539.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1738\/3813868\/crc-25-0539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1738\/3813868\/crc-25-0539.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:41:34Z","timestamp":1784832094000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/7\/1738\/786945\/A-Phase-Ib-Study-of-Chemoimmunotherapy-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0539","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33073016","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33073028","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33072998","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33073010","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33073022","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33073004","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33073034","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33073046","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046955","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046967","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046898","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046901","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046931","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046943","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046973","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33073040","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046961","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046919","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046907","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046937","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046949","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046913","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046925","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33073007","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33073019","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33073049","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046970","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33073043","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33073031","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33073025","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33073037","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33073001","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33073013","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046922","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046934","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046910","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046964","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046940","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046952","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046928","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046904","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046916","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046946","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33046958","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8607005","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}